These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33677043)

  • 1. Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.
    Tan G; Meier-Abt F
    Exp Hematol; 2021 May; 97():47-56.e5. PubMed ID: 33677043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.
    Tan G; Wolski WE; Kummer S; Hofstetter M; Theocharides APA; Manz MG; Aebersold R; Meier-Abt F
    Blood Adv; 2022 Jun; 6(11):3480-3493. PubMed ID: 35008095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea.
    Castello G; Lerza R; Cerruti A; Cavallini D; Bogliolo G; Pannacciulli I
    Ann Hematol; 1995 Sep; 71(3):119-21. PubMed ID: 7548329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia.
    Andréasson B; Swolin B; Kutti J
    Eur J Haematol; 2000 Mar; 64(3):188-93. PubMed ID: 10997885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients.
    Bogeska R; Pahl HL
    Stem Cells Transl Med; 2013 Feb; 2(2):112-7. PubMed ID: 23341442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
    Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained enhancement of OCTN1 transporter expression in association with hydroxyurea induced γ-globin expression in erythroid progenitors.
    Walker AL; Ofori-Acquah SF
    Exp Hematol; 2017 Jan; 45():69-73.e2. PubMed ID: 27616638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
    Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
    Alvarez-Larrán A; Díaz-González A; Such E; Mora E; Andrade-Campos M; García-Hernández C; Gómez-Casares MT; García-Gutiérrez V; Carreño-Tarragona G; Garrote M; Fernández-Ibarrondo L; Cervera J; Bellosillo B; Cervantes F; Hernández-Boluda JC;
    Leukemia; 2021 Feb; 35(2):623-627. PubMed ID: 32372025
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.
    Meier-Abt F; Wolski WE; Tan G; Kummer S; Amon S; Manz MG; Aebersold R; Theocharides APA
    Blood Cancer J; 2021 Feb; 11(2):31. PubMed ID: 33574218
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
    Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.
    Dai C; Chung IJ; Krantz SB
    Exp Hematol; 2005 Feb; 33(2):152-8. PubMed ID: 15676208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
    King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
    Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.